Ani Pharmaceuticals (ANIP) Cash & Current Investments (2016 - 2026)
Ani Pharmaceuticals' Cash & Current Investments history spans 16 years, with the latest figure at $285.6 million for Q4 2025.
- On a quarterly basis, Cash & Current Investments rose 97.12% to $285.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $285.6 million, a 97.12% increase, with the full-year FY2025 number at $285.6 million, up 97.12% from a year prior.
- Cash & Current Investments hit $285.6 million in Q4 2025 for Ani Pharmaceuticals, up from $262.6 million in the prior quarter.
- Over the last five years, Cash & Current Investments for ANIP hit a ceiling of $285.6 million in Q4 2025 and a floor of $15.3 million in Q3 2021.
- Historically, Cash & Current Investments has averaged $137.6 million across 5 years, with a median of $145.0 million in 2024.
- Biggest five-year swings in Cash & Current Investments: skyrocketed 718.38% in 2021 and later plummeted 49.45% in 2022.
- Tracing ANIP's Cash & Current Investments over 5 years: stood at $105.3 million in 2021, then plummeted by 49.45% to $53.2 million in 2022, then soared by 315.38% to $221.1 million in 2023, then crashed by 34.47% to $144.9 million in 2024, then soared by 97.12% to $285.6 million in 2025.
- Business Quant data shows Cash & Current Investments for ANIP at $285.6 million in Q4 2025, $262.6 million in Q3 2025, and $217.8 million in Q2 2025.